Researchmoz added Most up-to-date research on "Global Breakthrough Therapies Market Should Reach $99.2 Billion By 2022, At A CAGR Of 15.2% From 2017 To 2022" to its huge collection of research reports.
The global market for breakthrough therapy designation (BTD) drugs should reach $99.2 billion by 2022 from $48.8 billion in 2017 at a compound annual growth rate (CAGR) of 15.2%, from 2017 to 2022.
The cancer therapy segment of the breakthrough therapy designation drugs industry is the largest market. The market is expected to grow from $19.6 billion in 2017 to $58.6 billion in 2022 at a CAGR of 24.5% for the period 2017-2022.
The CNS and neurology therapy segment of the breakthrough therapy designation drugs industry is expected to grow from $956 million in 2017 to $8.4 billion in 2022 at a CAGR of 54.3% for the period 2017-2022.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1377102
Table Of Content
Chapter 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE REPORT
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
ANALYSTS' CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
Chapter 2 SUMMARY
Chapter 3 OVERVIEW
DEFINING BREAKTHROUGH THERAPY DESIGNATION
QUALIFYING CRITERIA FOR BREAKTHROUGH THERAPY DESIGNATION
THE BENEFITS OF BREAKTHROUGH THERAPY DESIGNATION
FDA'S APPROACHES TO EXPEDITED DRUG DEVELOPMENT
DRUGS GRANTED BREAKTHROUGH THERAPY DESIGNATION
PRIME (PRIORITY MEDICINE) SCHEME
Browse TOC @ https://www.researchmoz.us/breakthrough-therapies-market-dynamics-and-investment-opportunities-report.html/toc
Chapter 4 COMMERCIAL APPLICATION OF BREAKTHROUGH THERAPY DESIGNATION
INTRODUCTION
Serious Condition
Existing (or Available) Therapies
Preliminary Clinical Evidence
May Demonstrate Substantial Improvement on Clinically Significant Endpoint(s)
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM AND NEUROLOGICAL DISORDERS
INFECTIOUS DISEASES
ONCOLOGY
CV - BTD DRUGS APPROVED
Promacta/Revolade (Eltrombopag Olamine: Novartis/GlaxoSmithKline)
BTD: February 6, 2014
Drug Class: Thrombopoietin Receptor Agonist (Small Molecule)
Indication: Severe Aplastic Anemia (SAA; CV)
Clinical Stage: Approved
Forecast
Praxbind (Idarucizumab; Boehringer Ingelheim)
BTD: June 30, 2014
Drug Class: Humanized Antibody Fragment (Biologic)
Indication: Reversal of Bleeding and Clotting Associated with Pradaxa (CV)
Clinical Stage: Approved
Forecast
CV - BTD IN DEVELOPMENT
Reasanz (Serelaxin; Novartis)
BTD: June 21, 2013
Drug Class: Human Relaxin 2 Hormone (Biologic)
Indication: Acute Heart Failure (AHF; CV)
Clinical Stage
Forecast
Actemra/RoActemra (Tocilizumab; Roche)
BTD: June 10, 2015, and August 5, 2016
Drug Class: Humanized Anti Interleukin L-6 Receptor mAb (Biologic)
Indication: Systemic Sclerosis and Giant Cell Arteritis (CNS/Rare Disease)
Clinical Stage: Approved/Phase 3 BTD
The global market for breakthrough therapy designation (BTD) drugs should reach $99.2 billion by 2022 from $48.8 billion in 2017 at a compound annual growth rate (CAGR) of 15.2%, from 2017 to 2022.
The cancer therapy segment of the breakthrough therapy designation drugs industry is the largest market. The market is expected to grow from $19.6 billion in 2017 to $58.6 billion in 2022 at a CAGR of 24.5% for the period 2017-2022.
The CNS and neurology therapy segment of the breakthrough therapy designation drugs industry is expected to grow from $956 million in 2017 to $8.4 billion in 2022 at a CAGR of 54.3% for the period 2017-2022.
To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1377102
Table Of Content
Chapter 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE REPORT
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY AND INFORMATION SOURCES
ANALYSTS' CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
Chapter 2 SUMMARY
Chapter 3 OVERVIEW
DEFINING BREAKTHROUGH THERAPY DESIGNATION
QUALIFYING CRITERIA FOR BREAKTHROUGH THERAPY DESIGNATION
THE BENEFITS OF BREAKTHROUGH THERAPY DESIGNATION
FDA'S APPROACHES TO EXPEDITED DRUG DEVELOPMENT
DRUGS GRANTED BREAKTHROUGH THERAPY DESIGNATION
PRIME (PRIORITY MEDICINE) SCHEME
Browse TOC @ https://www.researchmoz.us/breakthrough-therapies-market-dynamics-and-investment-opportunities-report.html/toc
Chapter 4 COMMERCIAL APPLICATION OF BREAKTHROUGH THERAPY DESIGNATION
INTRODUCTION
Serious Condition
Existing (or Available) Therapies
Preliminary Clinical Evidence
May Demonstrate Substantial Improvement on Clinically Significant Endpoint(s)
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM AND NEUROLOGICAL DISORDERS
INFECTIOUS DISEASES
ONCOLOGY
CV - BTD DRUGS APPROVED
Promacta/Revolade (Eltrombopag Olamine: Novartis/GlaxoSmithKline)
BTD: February 6, 2014
Drug Class: Thrombopoietin Receptor Agonist (Small Molecule)
Indication: Severe Aplastic Anemia (SAA; CV)
Clinical Stage: Approved
Forecast
Praxbind (Idarucizumab; Boehringer Ingelheim)
BTD: June 30, 2014
Drug Class: Humanized Antibody Fragment (Biologic)
Indication: Reversal of Bleeding and Clotting Associated with Pradaxa (CV)
Clinical Stage: Approved
Forecast
CV - BTD IN DEVELOPMENT
Reasanz (Serelaxin; Novartis)
BTD: June 21, 2013
Drug Class: Human Relaxin 2 Hormone (Biologic)
Indication: Acute Heart Failure (AHF; CV)
Clinical Stage
Forecast
Actemra/RoActemra (Tocilizumab; Roche)
BTD: June 10, 2015, and August 5, 2016
Drug Class: Humanized Anti Interleukin L-6 Receptor mAb (Biologic)
Indication: Systemic Sclerosis and Giant Cell Arteritis (CNS/Rare Disease)
Clinical Stage: Approved/Phase 3 BTD
No comments:
Post a Comment